CamGene Therapeutics is a startup based in the United Kingdom, most recent round Seed, 2 tracked investors.
Based in the United Kingdom, CamGene Therapeutics is a startup founded in 2024. Its most recent tracked round is Seed. Brouky records 2 investors associated with the company.
CamGene Therapeutics is developing RNA-based therapeutics to address the underlying cellular dysfunction that causes hearing loss, an area where no restorative treatments currently exist. Their approach uses lipid-nanoparticle (LNP) delivered RNA therapies, including mRNA, siRNA, and antisense oligonucleotides, to modulate protein expression and regenerate or protect key cochlear cells, with the goal of creating the first mass-market therapeutic solution for hearing loss.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.